Logo

Pfizer and BioNTech's COVID-19 Vaccine Booster Receive the US FDA's EUA for the Treatment of COVID-19

Share this
Pfizer and BioNTech's COVID-19 Vaccine Booster Receive the US FDA's EUA for the Treatment of COVID-19

Pfizer and BioNTech's COVID-19 Vaccine Booster Receive the US FDA's EUA for the Treatment of COVID-19

Shots:

  • The US FDA has issued a EUA for the COVID-19 booster vaccine (administered at least 6mos. after completion of primary 2 doses) to prevent COVID-19 in individuals aged ≥65yrs. & 18 through 64yrs. of age who at high risk of severe COVID-19
  • The EUA is based on clinical data that showed higher neutralizing Ab titers against COVID-19 & other variants compared with the levels observed after 2 doses- frequency of reactions was similar or lower than after dose two & AEs was consistent with other clinical safety data
  • Previously- a third dose of the vaccine was authorized for individuals aged 12yrs. who have undergone a solid organ transplant or diagnosed with other conditions

 Ref: Pfizer | Image: Wall Street Journal

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions